Oral Semaglutide Exposure (eCavg) Predicts Weight Loss and GI Tolerability Better Than Dose for T2D Patients

Inter-individual variability in drug absorption poses a significant challenge for oral medications, particularly for GLP-1 receptor agonists (GLP-1RAs) like oral semaglutide. This variability can lead to inconsistent therapeutic outcomes in patients with Type 2 Diabetes (T2D), affecting both glycemic control and weight management. Standard fixed-dose regimens may not achieve optimal exposure for all individuals, potentially resulting in suboptimal efficacy or increased adverse events. Understanding the relationship between actual drug exposure and clinical outcomes, beyond just the prescribed dose, is crucial for personalizing treatment and improving patient care.

Researchers conducted a retrospective cohort study involving 256 participants with Type 2 Diabetes (T2D) who initiated oral semaglutide. For each patient, estimated individual exposure (eCavg) was calculated at follow-up visits using a validated population pharmacokinetic model. This model incorporated patient-specific factors such as dose, weight, sex, ethnicity, and pre-existing GI disorders, without requiring direct plasma semaglutide measurements. Mixed-effects models were employed to assess associations between both prescribed dose and eCavg with changes in HbA1c and percent body weight. For gastrointestinal (GI) side effects, time-adjusted fixed-effects logistic regression was utilized.

Over a median follow-up of 19 months, the cohort demonstrated significant improvements: HbA1c declined by 0.7%, and body weight decreased by 7.5%. However, 41.8% of patients reported experiencing GI side effects. Both the prescribed dose and estimated individual exposure (eCavg) were significantly associated with all measured outcomes when analyzed independently. When comparing model fit, the dose model outperformed the eCavg model for predicting ΔHbA1c (p < 0.01).